The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent acute coronary syndrome and the AA genotype in the ADCY9 gene.
- Subjects with the appropriate genetic background and recently hospitalized for ACS (between 1 and 3 months).
- Male and female subjects age 45 years and over at Visit 1.
- AA genotype variant in the ADCY9 gene.
Detailed eligibility discussed when you contact the study team.